Skip to main page content
Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

My NCBI Filters
Text availability
Article attribute
Article type
Publication date

Search Results

9 results
Filters applied: . Clear all
Page 1
Nationwide Outcomes of Advanced Melanoma According to BRAFV600 Status.
van Breeschoten J, Wouters MWJM, de Wreede LC, Hilarius DH, Haanen JB, Blank CU, Aarts MJB, van den Berkmortel FWPJ, de Groot JB, Hospers GAP, Kapiteijn E, Piersma D, van Rijn RS, Suijkerbuijk KPM, Blokx WAM, Ten Tije AJ, van der Veldt AAM, Vreugdenhil G, Boers MJ, van den Eertwegh AJM. van Breeschoten J, et al. Am J Clin Oncol. 2021 Feb 1;44(2):82-89. doi: 10.1097/COC.0000000000000786. Am J Clin Oncol. 2021. PMID: 33332931
The unfavorable effects of COVID-19 on Dutch advanced melanoma care.
van Not OJ, van Breeschoten J, van den Eertwegh AJM, Hilarius DL, De Meza MM, Haanen JB, Blank CU, Aarts MJB, van den Berkmortel FWPJ, de Groot JWB, Hospers GAP, Ismail RK, Kapiteijn E, Piersma D, van Rijn RS, Stevense-den Boer MAM, van der Veldt AAM, Vreugdenhil G, Boers-Sonderen MJ, Blokx WAM, Suijkerbuijk KPM, Wouters MWJM. van Not OJ, et al. Among authors: van breeschoten j. Int J Cancer. 2021 Oct 3. doi: 10.1002/ijc.33833. Online ahead of print. Int J Cancer. 2021. PMID: 34605003
An invisible group of COVID-19 victims; impact on Dutch lung cancer care.
van Breeschoten J, Ismail R, Smit H, Schuurbiers O, Schramel F; Dutch Lung Cancer Audit Scientific Committee. van Breeschoten J, et al. Lung Cancer. 2021 Sep;159:177-178. doi: 10.1016/j.lungcan.2021.06.023. Epub 2021 Jul 19. Lung Cancer. 2021. PMID: 34303539 Free PMC article. No abstract available.
Adjuvant treatment for melanoma in clinical practice - Trial versus reality.
de Meza MM, Ismail RK, Rauwerdink D, van Not OJ, van Breeschoten J, Blokx WAM, de Boer A, van Dartel M, Hilarius DL, Ellebaek E, Bonenkamp HJ, Blank CU, Aarts MJB, van Akkooi ACJ, van den Berkmortel FWPJ, Boers-Sonderen MJ, de Groot JWB, Haanen JB, Hospers GAP, Kapiteijn EW, Piersma D, van Rijn RS, van der Veldt AAM, Vreugdenhil A, Westgeest HM, van den Eertwegh AJM, Suijkerbuijk KPM, Wouters MWJM. de Meza MM, et al. Among authors: van breeschoten j. Eur J Cancer. 2021 Nov;158:234-245. doi: 10.1016/j.ejca.2021.08.044. Epub 2021 Sep 29. Eur J Cancer. 2021. PMID: 34600790 Free article.
First-line BRAF/MEK inhibitors versus anti-PD-1 monotherapy in BRAFV600-mutant advanced melanoma patients: a propensity-matched survival analysis.
van Breeschoten J, Wouters MWJM, Hilarius DL, Haanen JB, Blank CU, Aarts MJB, van den Berkmortel FWPJ, de Groot JB, Hospers GAP, Kapiteijn E, Piersma D, van Rijn RS, Suijkerbuijk KPM, Blokx WAM, Tije BJT, Veldt AAMV, Vreugdenhil A, Boers-Sonderen MJ, van den Eertwegh AJM. van Breeschoten J, et al. Br J Cancer. 2021 Mar;124(7):1222-1230. doi: 10.1038/s41416-020-01229-1. Epub 2021 Jan 26. Br J Cancer. 2021. PMID: 33495600
Trends in Use and Perceptions About Triplet Chemotherapy Plus Bevacizumab for Metastatic Colorectal Cancer.
van Nassau SC, Bond MJ, Scheerman I, van Breeschoten J, Kessels R, Valkenburg-van Iersel LB, Verheul HM, Buffart TE, Mekenkamp LJ, Lemmens VE, Koopman M, Bol GM; EXCITE (From Clinical Trial to Bedside: Triplet Chemotherapy in Metastatic Colorectal Cancer) Study Group. van Nassau SC, et al. Among authors: van breeschoten j. JAMA Netw Open. 2021 Sep 1;4(9):e2124766. doi: 10.1001/jamanetworkopen.2021.24766. JAMA Netw Open. 2021. PMID: 34505885 Free PMC article.
Hospital Variation in Cancer Treatments and Survival OutComes of Advanced Melanoma Patients: Nationwide Quality Assurance in The Netherlands.
van Breeschoten J, van den Eertwegh AJM, de Wreede LC, Hilarius DL, van Zwet EW, Haanen JB, Blank CU, Aarts MJB, van den Berkmortel FWPJ, de Groot JWB, Hospers GAP, Kapiteijn E, Piersma D, van Rijn RS, Stevense-den Boer MAM, van der Veldt AAM, Vreugdenhil G, Boers-Sonderen MJ, Suijkerbuijk KPM, Wouters MWJM. van Breeschoten J, et al. Cancers (Basel). 2021 Oct 11;13(20):5077. doi: 10.3390/cancers13205077. Cancers (Basel). 2021. PMID: 34680228 Free PMC article.
Safety and Efficacy of Checkpoint Inhibition in Patients With Melanoma and Preexisting Autoimmune Disease : A Cohort Study.
van der Kooij MK, Suijkerbuijk KPM, Aarts MJB, van den Berkmortel FWPJ, Blank CU, Boers-Sonderen MJ, van Breeschoten J, van den Eertwegh AJM, de Groot JWB, Haanen JBAG, Hospers GAP, Piersma D, van Rijn RS, Ten Tije AJ, van der Veldt AAM, Vreugdenhil G, van Zeijl MCT, Wouters MWJM, Dekkers OM, Kapiteijn E. van der Kooij MK, et al. Among authors: van breeschoten j. Ann Intern Med. 2021 May;174(5):641-648. doi: 10.7326/M20-3419. Epub 2021 Feb 16. Ann Intern Med. 2021. PMID: 33587686
Correction: First-line BRAF/MEK inhibitors versus anti-PD-1 monotherapy in BRAFV600-mutant advanced melanoma patients: a propensity-matched survival analysis.
van Breeschoten J, Wouters MWJM, Hilarius DL, Haanen JB, Blank CU, Aarts MJB, van den Berkmortel FWPJ, de Groot JB, Hospers GAP, Kapiteijn E, Piersma D, van Rijn RS, Suijkerbuijk KPM, Blokx WAM, Ten Tije BJ, van der Veldt AAM, Vreugdenhil A, Boers-Sonderen MJ, van den Eertwegh AJM. van Breeschoten J, et al. Br J Cancer. 2021 May;124(10):1746. doi: 10.1038/s41416-021-01312-1. Br J Cancer. 2021. PMID: 33723402 Free PMC article. No abstract available.